Literature DB >> 22749622

Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia.

Beenish Nafees1, Patricia van Hanswijck de Jonge, Donald Stull, Katie Pascoe, Martin Price, Amory Clarke, Douglas Turkington.   

Abstract

OBJECTIVE: The construct validity and test-retest reliability of the Personal and Social Performance (PSP) scale were used to assess social functioning in a cohort of ethnically diverse UK patients with schizophrenia.
METHODS: A total of 73 patients with schizophrenia took part in the study. At baseline, the PSP, two symptomatology scales and two other functioning scales were administered. A subset of the sample (N=40) took part in a retest where the Clinical Global Impression-Severity (CGI-S) and PSP scales were administered 8-10 days later.
RESULTS: PSP significantly correlated with all other measures, Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF) and Quality of Life Scale (QLS) at baseline (p<0.02) and with CGI-S at follow-up (p<0.01). In addition, the PSP scale was moderately sensitive to the severity of illness. Test-retest reliability for the PSP score was 0.45 and the scale was able to discriminate between known groups (mild and severe patients).
CONCLUSION: The PSP was easy to administer in this predominantly inpatient cohort and was moderately correlated with all other functioning measures tested. Due to patient homogeneity, the test-retest reliability statistic of the PSP was lower than that observed in other studies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22749622     DOI: 10.1016/j.schres.2012.06.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Predictors of Return to Work for People with Anxiety or Depression Participating in a Randomized Trial Investigating the Effect of a Supported Employment Intervention.

Authors:  Lone Hellström; Thomas Nordahl Christensen; Anders Bo Bojesen; Lene Falgaard Eplov
Journal:  J Occup Rehabil       Date:  2022-05-25

2.  Systematic review of global functioning and quality of life in people with psychotic disorders.

Authors:  A G Nevarez-Flores; K Sanderson; M Breslin; V J Carr; V A Morgan; A L Neil
Journal:  Epidemiol Psychiatr Sci       Date:  2018-10-01       Impact factor: 6.892

3.  Defining Occupational Competence and Occupational Identity in the Context of Recovery in Schizophrenia.

Authors:  Bhing-Leet Tan; Madeline Wei Zhen Lim; Huiting Xie; Ziqiang Li; Jimmy Lee
Journal:  Am J Occup Ther       Date:  2020 Jul/Aug

4.  A comparison of thought and perception disorders in borderline personality disorder and schizophrenia: psychotic experiences as a reaction to impaired social functioning.

Authors:  Francesco Oliva; Marinella Dalmotto; Elvezio Pirfo; Pier Maria Furlan; Rocco Luigi Picci
Journal:  BMC Psychiatry       Date:  2014-10-03       Impact factor: 3.630

5.  Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole.

Authors:  Timothy Peters-Strickland; Linda Pestreich; Ainslie Hatch; Shashank Rohatagi; Ross A Baker; John P Docherty; Lada Markovtsova; Praveen Raja; Peter J Weiden; David P Walling
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-11       Impact factor: 2.570

6.  Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis.

Authors:  Sandra Bucci; Christine Barrowclough; John Ainsworth; Matthew Machin; Rohan Morris; Katherine Berry; Richard Emsley; Shon Lewis; Dawn Edge; Iain Buchan; Gillian Haddock
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

7.  An Asian study on clinical and psychological factors associated with personal recovery in people with psychosis.

Authors:  Madeline Lim; Ziqiang Li; Huiting Xie; Bhing Leet Tan; Jimmy Lee
Journal:  BMC Psychiatry       Date:  2019-08-22       Impact factor: 3.630

Review 8.  Review of depot aripiprazole for schizophrenia.

Authors:  Farha Bilal Motiwala; Kim Stasia Siscoe; Rif S El-Mallakh
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

9.  The effect of IPS-modified, an early intervention for people with mood and anxiety disorders: study protocol for a randomised clinical superiority trial.

Authors:  Lone Hellström; Per Bech; Merete Nordentoft; Jane Lindschou; Lene Falgaard Eplov
Journal:  Trials       Date:  2013-12-24       Impact factor: 2.279

10.  Towards a framework for treatment effectiveness in schizophrenia.

Authors:  Georg Juckel; Andrea de Bartolomeis; Philip Gorwood; Sergey Mosolov; Luca Pani; Alessandro Rossi; Julio Sanjuan
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.